Takeda news

CAMBRIDGE, Mass., SEPTEMBER 11, 2009 – Takeda Pharmaceutical Company Limited (TSE:4502) and its wholly-owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of the Phase II portion of a Phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer.

Osaka, Japan, September 10, 2009 --- Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka; President: Yasuchika Hasegawa, “Takeda”) announced today that it has introduced Cisco TelePresence™, －an advanced videoconferencing system providing both high-resolution visuals and a high-quality audio environment. Cisco TelePresence™ was provided by Cisco Systems G.K.

DEERFIELD, Ill., and OSAKA, Japan, September 4, 2009 – Takeda Pharmaceutical Company Limited (“Takeda”) today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME) a complete response letter from the U.S.

Tokyo and Osaka, Japan, September 3, 2009 - Terumo Corporation (Head Office: Shibuya-ku, Tokyo; President: Akira Takahashi, “Terumo”) and Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka; President: Yasuchika Hasegawa, “Takeda”) announced jointly today that the two companies will commence in coming October the co-promotion of ethical narcotic formulations that Takeda is manufactu

Liestal, Switzerland (September 2, 2009) and Osaka, Japan (September 3,2009) – Santhera Pharmaceuticals (SIX: SANN, “Santhera”), a Swiss specialty pharmaceutical company focused on orphan neuromuscular diseases, and Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) announced today that Santhera has initiated the pivotal Phase III study with Catena®/Sovrima® (INN: Idebenone) for the treat

Home